Fig. 1

T007 inhibited RANKL-induced osteoclastogenesis in a time- and dose-dependent manner without cytotoxic effects in vitro. a The structure of T007. b Effects of T007 on BMMs viability by CCK8 assays at 48 and 96 h. c IC50 values obtained for the activity of T007 against BMMs. d BMMs were treated with various concentrations of T007, M-CSF (25 ng/mL) and RANKL (50 ng/mL) for 7 days. e The number, area and size of TRAP-positive multinuclear cells. f TRAP-positive BMMs following the treatment with 0.6 μM T007 for the indicated days during osteoclastogenesis. g Quantification of TRAP-positive multinuclear cells, area of osteoclasts, osteoclast number and size. All experiments were performed at least three times. Scale bar, 100 μm. *P < 0.05 and **P < 0.01 compared with the control group